According to filings with the U.S. Securities and Exchange Commission, Subtle Medical has raised $33 Million in new Series C funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Morgan Stanley Expansion Capital, Shinhan Venture Investment, Fusion Fund, EnvisionX, BRV, and Samsung Ventures

About Subtle Medical
Subtle Medical is a leading provider of AI-powered imaging solutions, optimizing scan efficiency and image quality across radiology. Recognized by TIME as a World’s Top Healthcare Company (2025), an Nvidia Inception Award winner, and multiple times as a CB Insights GenAI 50, Digital Health 150, and Top AI 100 company, Subtle Medical is committed to transforming medical imaging through responsible and intelligent software. The company’s solutions are deployed on over 1,300 scanners worldwide, helping imaging centers and hospitals deliver faster scans, improve image quality, and enhance patient care without the need for new hardware.

To learn more, visit https://subtlemedical.com/
Linkedin: https://www.linkedin.com/company/subtlemedical/

Contact:
Ohad Arazi, Chief Executive Officer
https://www.linkedin.com/in/ohad-arazi-44492293/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.